NCT04300257

Brief Summary

The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and treatment procedures.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
44mo left

Started Oct 2019

Longer than P75 for all trials

Geographic Reach
1 country

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
Oct 2019Dec 2029

Study Start

First participant enrolled

October 19, 2019

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

February 20, 2020

Completed
18 days until next milestone

First Posted

Study publicly available on registry

March 9, 2020

Completed
9.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

March 20, 2024

Status Verified

March 1, 2024

Enrollment Period

10.2 years

First QC Date

February 20, 2020

Last Update Submit

March 19, 2024

Conditions

Sarcoma

Keywords

Sarcoma, EpithelioidSarcoma, Soft TissueSarcoma, Spindle CellSarcoma, Bone

Outcome Measures

Primary Outcomes (12)

  • Diagnosis,

    Data collected in the registry will be evaluated and analyzed to determine criteria to improve treatment strategies

    5 years

  • Local recurrence,

    s.o.

    5 years

  • distant metastasis,

    s.o.

    5 years

  • biopsy taken by operating surgeon-radiologist-team,

    s.o.

    5 years

  • pathology centrally reviewed,

    s.o.

    5 years

  • Surgery (yes/no),

    s.o.

    5 years

  • Surgical margin status,

    s.o.

    5 years

  • surgery performed by dedicated surgeon,

    s.o.

    5 years

  • Radiation Therapy (yes/no),

    s.o.

    5 years

  • Chemotherapy (yes/no),

    s.o.

    5 years

  • decision of board carried out,

    s.o.

    5 years

  • Status at last contact,

    s.o.

    5 years

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients suffering from bone or soft tissue tumors.

You may qualify if:

  • Malignant and intermediate and selected benign bone or soft tissue tumors, acc. to the WHO coding list of the SSN
  • Female and male subjects of all ages

You may not qualify if:

  • Documented objection of subsequent use of personal health data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Kantonsspital Winterthur

Winterthur, Canton of Zurich, 8400, Switzerland

RECRUITING

SwissSarcomaNetwork

Winterthur, Canton of Zurich, 8400, Switzerland

RECRUITING

Ente Ospedaliero Cantonale

Bellinzona, Canton Ticino, 6500, Switzerland

RECRUITING

Kantonsspital Graubünden

Chur, Kanton Graubünden, 7000, Switzerland

RECRUITING

Luzerner Kantonsspital

Lucerne, 6000, Switzerland

RECRUITING

Pathologie Institut Enge

Zurich, 8005, Switzerland

RECRUITING

Klinik Hirslanden

Zurich, 8032, Switzerland

RECRUITING

Stadtspital Zürich Triemli

Zurich, 8063, Switzerland

RECRUITING

Related Publications (2)

  • Andritsch E, Beishon M, Bielack S, Bonvalot S, Casali P, Crul M, Delgado Bolton R, Donati DM, Douis H, Haas R, Hogendoorn P, Kozhaeva O, Lavender V, Lovey J, Negrouk A, Pereira P, Roca P, de Lempdes GR, Saarto T, van Berck B, Vassal G, Wartenberg M, Yared W, Costa A, Naredi P. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017 Feb;110:94-105. doi: 10.1016/j.critrevonc.2016.12.002. Epub 2016 Dec 8.

    PMID: 28109409RESULT

  • Abarca T, Gao Y, Monga V, Tanas MR, Milhem MM, Miller BJ. Improved survival for extremity soft tissue sarcoma treated in high-volume facilities. J Surg Oncol. 2018 Jun;117(7):1479-1486. doi: 10.1002/jso.25052. Epub 2018 Apr 6.

    PMID: 29633281RESULT

MeSH Terms

Conditions

SarcomaOsteosarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsNeoplasms, Bone TissueNeoplasms, Connective Tissue

Study Officials

  • Bruno Fuchs, Prof

    SwissSarcomaNetwork

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bruno Fuchs, Prof.

CONTACT

+41 52 266 25 33bruno.fuchs@ksw.ch

Larissa Slater

CONTACT

+41 52 266 24 88larissa.slater@ksw.ch

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 20, 2020

First Posted

March 9, 2020

Study Start

October 19, 2019

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

March 20, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations

CH(8)